CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country

被引:2
|
作者
Sulaiman, Noor Yuhyi [1 ]
Anuar, Nur Adila [1 ]
Arshad, Normala [1 ]
Cheong, Chin Sum [1 ]
Liong, Chee Chiat [1 ]
Khairullah, Shasha [1 ]
Chin, Edmund Fui Min [1 ]
Bee, Ping Chong [1 ]
Sam, I. Ching [2 ]
Iyadorai, Thevambiga [2 ]
Gan, Gin Gin [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia
[2] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia
关键词
Hematopoietic stem cell transplantation; Cytomegalovirus prevalence; Cytomegalovirus infection; Southeast Asia; Malaysia; EARLY CYTOMEGALOVIRUS REACTIVATION; RISK-FACTORS; BLOOD-DONORS; MORTALITY; DISEASE; SEROPREVALENCE; PREVENTION; LEUKEMIA; ERA; DNA;
D O I
10.1007/s12288-023-01655-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytomegalovirus (CMV) infection is one of the common complications which can lead to significant morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT). As the seroprevalence of CMV infection in Malaysia is high, this study aims to determine the prevalence of CMV infection in patients post HSCT and to evaluate the associated risk factors. Patients who underwent allogeneic HSCT in adult ward from 2008 to 2020 at a tertiary teaching hospital in Kuala Lumpur, Malaysia were studied retrospectively. They were followed up for a minimum of 100 days post-HSCT to determine the incidence of CMV infection. CMV infection was defined according to CMV Drug Development Forum 2014. Risk factors such as type of transplant, serostatus of donor and patients, age, gender, race, presence of graft versus host disease (GVHD) and underlying disease were included for analysis. A total of 112 patients were included. Forty (35.7%) patients had CMV infection with median of onset recorded as 40 days (range 13-95 days). Only haplo-identical HSCT and presence of GVHD were identified as significant risk factors. Patients who had CMV infection had a lower median survival time although this was not statistically significant. The CMV infection rate was comparable with previous reports in Asia and as expected, higher than the western countries. Therefore, vigilant monitoring of CMV infection should be implemented especially in patients who had haplo-identical HSCT and acute GVHD.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 50 条
  • [1] CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country
    Noor Yuhyi Sulaiman
    Nur Adila Anuar
    Normala Arshad
    Chin Sum Cheong
    Chee Chiat Liong
    Shasha Khairullah
    Edmund Fui Min Chin
    Ping Chong Bee
    I Ching Sam
    Thevambiga Iyadorai
    Gin Gin Gan
    [J]. Indian Journal of Hematology and Blood Transfusion, 2024, 40 : 97 - 102
  • [2] Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation
    Maffini, Enrico
    Giaccone, Luisa
    Festuccia, Moreno
    Brunello, Lucia
    Busca, Alessandro
    Bruno, Benedetto
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (06) : 585 - 596
  • [3] Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
    Dieamant, Debora C.
    Bonon, Sandra H. A.
    Peres, Renata M. B.
    Costa, Claudia R. C.
    Albuquerque, Dulcineia M.
    Miranda, Eliana C. M.
    Aranha, Francisco J. P.
    Oliveira-Duarte, Gislaine
    Fernandes, Virginio C. A.
    De Souza, Carmino A.
    Costa, Sandra C. B.
    Vigorito, Afonso C.
    [J]. BMC INFECTIOUS DISEASES, 2013, 13
  • [4] Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
    Débora C Dieamant
    Sandra HA Bonon
    Renata MB Peres
    Claudia RC Costa
    Dúlcinéia M Albuquerque
    Eliana CM Miranda
    Francisco JP Aranha
    Gislaine Oliveira-Duarte
    Virginio CA Fernandes
    Carmino A De Souza
    Sandra CB Costa
    Afonso C Vigorito
    [J]. BMC Infectious Diseases, 13
  • [5] Pre-emptive therapy of CMV infection in allogeneic hematopoietic stem cell transplantation.
    Dentamaro, T
    Cudillo, L
    Picardi, A
    Postorino, M
    Gallone, D
    Masi, M
    Amadori, S
    [J]. BONE MARROW TRANSPLANTATION, 1999, 23 : S63 - S63
  • [6] An experimental and clinical study of CMV infection after allogeneic hematopoietic stem cell transplantation.
    Wu, DP
    Wu, XJ
    Li, CX
    Ma, X
    Sun, AN
    [J]. BLOOD, 2004, 104 (11) : 354B - 354B
  • [7] Incidence of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell recipients at low risk of CMV infection
    Mori, T
    Okamoto, S
    Watanabe, R
    Yamazaki, R
    Tsukada, Y
    Nagayama, H
    Ishida, A
    Ikeda, Y
    [J]. BONE MARROW TRANSPLANTATION, 2002, 29 (12) : 1005 - 1006
  • [8] Adjusting BuCy 2 in Allogeneic Hematopoietic Stem Cell Transplantation to Improve Outcomes: Experience of a Limited-Resource Center in a Developing Country
    Franco, Monica Magdalena Rivera
    Rodriguez, Eucario Leon
    [J]. BLOOD, 2019, 134
  • [9] Oral valganciclovir is safe and effective as preemptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
    Ayala, E
    Greene, J
    Sandin, R
    Perkins, J
    Field, T
    Tate, C
    Goldstein, SC
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 31 - 31
  • [10] Incidence of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell recipients at low risk of CMV infection
    T Mori
    S Okamoto
    R Watanabe
    R Yamazaki
    Y Tsukada
    H Nagayama
    A Ishida
    Y Ikeda
    [J]. Bone Marrow Transplantation, 2002, 29 : 1005 - 1006